| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Lifecome Biochemistry Co.,Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥15.28 |
| 52 Week High | CN¥33.00 |
| 52 Week Low | CN¥11.00 |
| Beta | 0.74 |
| 11 Month Change | 23.72% |
| 3 Month Change | 16.02% |
| 1 Year Change | -43.64% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -67.57% |
Recent News & Updates
Recent updates
Shareholder Returns
| 002868 | CN Biotechs | CN Market | |
|---|---|---|---|
| 7D | 10.0% | 13.2% | 9.9% |
| 1Y | -43.6% | -7.6% | 1.2% |
Return vs Industry: 002868 underperformed the CN Biotechs industry which returned -7.6% over the past year.
Return vs Market: 002868 underperformed the CN Market which returned 1.2% over the past year.
Price Volatility
| 002868 volatility | |
|---|---|
| 002868 Average Weekly Movement | 7.6% |
| Biotechs Industry Average Movement | 7.1% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in CN Market | 9.4% |
| 10% least volatile stocks in CN Market | 4.5% |
Stable Share Price: 002868 has not had significant price volatility in the past 3 months compared to the CN market.
Volatility Over Time: 002868's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2003 | 992 | Tanping Lai | www.pclifecome.com |
Lifecome Biochemistry Co.,Ltd. operates as a biopharmaceutical company in China. It offers bacitracin zinc products, colistin sulfate products, probiotics products, bacitracin methylene disalicylate products, biological preservatives, etc.; veterinary drugs; and food preservatives.
Lifecome Biochemistry Co.,Ltd. Fundamentals Summary
| 002868 fundamental statistics | |
|---|---|
| Market cap | CN¥2.37b |
| Earnings (TTM) | -CN¥262.23m |
| Revenue (TTM) | CN¥603.39m |
3.9x
P/S Ratio-9.1x
P/E RatioIs 002868 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 002868 income statement (TTM) | |
|---|---|
| Revenue | CN¥603.39m |
| Cost of Revenue | CN¥733.69m |
| Gross Profit | -CN¥130.30m |
| Other Expenses | CN¥131.94m |
| Earnings | -CN¥262.23m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Oct 31, 2024
| Earnings per share (EPS) | -1.69 |
| Gross Margin | -21.59% |
| Net Profit Margin | -43.46% |
| Debt/Equity Ratio | 288.3% |
How did 002868 perform over the long term?
See historical performance and comparison